MAAT PHARMA | Finanzwire

Basculer en Français

11143	Companies
245554	Keywords
173596	Articles
132483	Press releases

Home
Companies
MAAT PHARMA

BRIEF

published on 10/07/2026 at 14:15, 1 hour 40 minutes ago

MaaT Pharma Faces Uncertainty Following CHMP Setback

Strategic Review Funding Challenges MaaT Pharma CHMP Opinion PHOENIX Trial
PRESS RELEASE

published on 10/07/2026 at 14:10, 1 hour 45 minutes ago

Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Under Review
First Berlin Equity Research updates its recommendation on MaaT Pharma SACA, ISIN: FR0012634822, to 'Under Review' after CHMP issues negative opinion on MaaT013, impacting European approval. Future focuses on PHOENIX phase 3 trial and funding challenges

First Berlin Equity Research Under Review CHMP MaaT Pharma SACA PHOENIX Phase 3 Trial
BRIEF

published on 09/21/2026 at 19:05, 15 days 20 hours ago

MaaT Pharma Advances MaaT034 for Clinical Trials in Solid Tumors

Clinical Trials Solid Tumors MaaT Pharma FDA Meeting MaaT034
PRESS RELEASE

published on 09/21/2026 at 19:00, 15 days 20 hours ago

Inside Information / Other news releases
MaaT Pharma announces Pre-IND meeting with FDA for MaaT034 clinical development in solid tumors. Company advances microbiome therapies for cancer patients through immune modulation

FDA MaaT Pharma Pre-IND Meeting MaaT034 Microbiome Therapies
BRIEF

published on 09/18/2026 at 07:35, 19 days 8 hours ago

MaaT Pharma Faces Setback with CHMP Decision on MaaT013

Clinical Trial MaaT013 CHMP Decision PHOENIX Study Regulatory Plan
PRESS RELEASE

published on 09/18/2026 at 07:30, 19 days 8 hours ago

Inside Information / Other news releases
MaaT Pharma provides update on CHMP negative opinion for MaaT013 (Xervyteg) development plan, focusing on Phase 3 trial PHOENIX. FDA support noted for potential patient enrollment in H1 2027

FDA Phase 3 Trial MaaT Pharma CHMP MaaT013
BRIEF

published on 09/15/2026 at 07:35, 22 days 8 hours ago

MaaT Pharma: unfavorable vote by the CHMP for MaaT013

MaaT Pharma MaaT013 CHAMP Negative Vote Randomized Trial
PRESS RELEASE

published on 09/15/2026 at 07:30, 22 days 8 hours ago

Inside Information / Other news releases
MaaT Pharma receives negative CHMP trend vote for MaaT013 (Xervyteg) conditional marketing authorization application in Europe. Company vows to explore options for patient access

MaaT Pharma CHMP Clinical Benefit Xervyteg Negative Trend
BRIEF

published on 07/24/2026 at 12:17, 2 months 14 days ago

Invus Public Equities reduces its stake in MAAT PHARMA

Voting Rights Threshold Crossing Transfer Of Shares MaaT Pharma Invus
BRIEF

published on 07/02/2026 at 18:35, 3 months 4 days ago

Current status of MaaT Pharma shares and voting rights

Euronext Paris Voting Rights Biotechnology Actions MaaT Pharma

1 2 ... 7

Accesswire

Published on 10/07/2026 at 15:30, 25 minutes ago

Gold Port Announces Marketing Agreement with NAI Interactive Ltd.
Published on 10/07/2026 at 14:30, 1 hour 25 minutes ago

Secure Blockchain's Agentic Solutions Signs Financial Services Firm, Expanding Enterprise AI Into Corporate Finance
Published on 10/07/2026 at 13:33, 2 hours 22 minutes ago

BULGOLD Samples 21.2g/t Gold at Surface and Expands Kopernica Footprint by 170% to 1,700 Metres by 800 Metres, Lutila Project
Published on 10/07/2026 at 13:00, 2 hours 55 minutes ago

ATHA Energy Successfully Completes Diamond Drilling at RIB North Discovery, Expanding Strike Length To 3.4 Km, And Identifies a Higher-Grade Sub Zone: Results Include RIBN-DD-023 Intersecting 19.5 M Of Composite Uranium Mineralization With 2.0 M Of High-G
Published on 10/07/2026 at 11:00, 4 hours 55 minutes ago

GMV Minerals Announces Assays from 2026 Diamond Drill Program including: 12.64 gpt Gold over 4.88 m in MHC26-14

View all ACCESSWIRE

EQS Group

Published on 10/07/2026 at 15:45, 10 minutes ago

EQS-Adhoc: VINCORION SE: VINCORION SE reports 41% higher revenue for the first 9 months of 2026 compared to the same period last year; Full-Year Guidance raised
Published on 10/07/2026 at 14:58, 57 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 10/07/2026 at 14:58, 57 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DCC plc
Published on 10/07/2026 at 14:57, 58 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Tate & Lyle plc
Published on 10/07/2026 at 14:56, 58 minutes ago

Form 8.3 - The Vanguard Group, Inc.: easyJet plc

Les Echos

Published on 10/07/2026 at 08:15, 7 hours 40 minutes ago

EURAZEO TO ACQUIRE MIYA WATER, A GLOBAL SPECIALIST IN EFFICIENT WATER MANAGEMENT SOLUTIONS
Published on 10/07/2026 at 08:00, 7 hours 55 minutes ago

Neoen launches construction of its 346 MW Goyder North Wind Farm in South Australia
Published on 10/06/2026 at 19:15, 20 hours 40 minutes ago

Air Liquide has successfully issued a 2 billion euros multi-tranche bond
Published on 10/06/2026 at 18:39, 21 hours 15 minutes ago

Total number of voting rights and shares making up the share capital at September 30, 2026
Published on 10/06/2026 at 18:15, 21 hours 40 minutes ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 30/09/2026

View all LES ECHOS COMFI WIRE